DEVELOPMENT AND OPTIMIZATION OF SOLID LIPID NANOPARTICLES OF ERLOTINIB USING DESIGN OF EXPERIMENTS: IN VITRO DRUGRELEASE AND IN VIVO PHARMACOKINETIC STUDIES

CHANDU VAMSHI GANGULA; SEEMA TOMAR; POLI REDDYPAPAGATLA

doi:10.22159/ijap.2025v17i5.53909

Authors

CHANDU VAMSHI GANGULA Department of Pharmaceutics, FoPS, Motherhood University, Roorkee, India
SEEMA TOMAR HOD Pharmaceutical Chemistry, FoPS, Motherhood University, Roorkee, India
POLI REDDYPAPAGATLA Department of Pharmacology, Nalanda College of Pharmacy, Nalgonda, Telangana, India

DOI:

https://doi.org/10.22159/ijap.2025v17i5.53909

Keywords:

Erlotinib, Nanoparticles, Lauric acid, Design of experiments, In vivo pharmacokinetics

Abstract

Objective: This study aimed to develop and optimize erlotinib-loaded solid lipid nanoparticles (ERL-SLNs) using response surface methodology (RSM) with a box-behnken design. The goal was to enhance the drug's solubility, stability, and bioavailability by optimizing key formulation parameters and evaluating the in vitro and in vivo performance of the nanoparticles.

Methods: ERL-SLNs were prepared using the hot homogenization method. Key formulation parameters, including the Quantity of Lipid, Concentration of Tween 80, and Homogenization Time, were optimized using RSM to achieve desirable characteristics such as Particle Size, Entrapment Efficiency, and Zeta Potential. The optimized ERL-SLNs were characterized for in vitro drug release using dissolution studies and fitted to various kinetic models. In vivo pharmacokinetic studies were conducted to evaluate the drug's bioavailability, maximum plasma concentration (Cmax), time to maximum concentration (Tmax), and half-life (t½) in comparison to conventional Erlotinib.

Results: The optimized ERL-SLNs exhibited a Particle Size of 152.8 nm, Entrapment Efficiency of 87.6%, and Zeta Potential of-23.4 mV. The in vitro drug release study demonstrated a significant enhancement in the release profile of ERL-SLNs (85.4% in 24 h) compared to free Erlotinib (42.3% in 24 h). The release kinetics best fit the Korsmeyer-Peppas model (R² = 0.9942, n = 0.71), indicating a non-Fickian diffusion mechanism involving both drug diffusion and nanoparticle erosion. Pharmacokinetic analysis revealed a higher Cmax (1408.35 ng/ml) for ERL-SLNs compared to conventional Erlotinib (1185.81 ng/ml), along with a prolonged Tmax (6 h vs. 4 h) and extended t½ (6.88 h vs. 3.7 h).

Conclusion: The study demonstrates that ERL-SLNs significantly improve the solubility, stability, and bioavailability of Erlotinib. The optimized formulation exhibited controlled drug release, enhanced pharmacokinetic properties, and prolonged therapeutic efficacy, highlighting its potential as an effective drug delivery system for Erlotinib.

References

1. Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non small cell lung cancer. J Oncol Pract. 2012;8(1):63-6. doi: 10.1200/JOP.2011.000374, PMID 22548014.

2. OB. Pharmacotherapy of non-small cell lung cancer: a short review. Asian J Pharm Clin Res. 2018;11(3):7-10. doi: 10.22159/ajpcr.2018.v11i3.23253.

3. Erdogar N. Development of oral tablet formulation containing erlotinib: randomly methylated-β-cyclodextrin inclusion complex using direct compression method. Turk J Pharm Sci. 2021;18(5):589-96. doi: 10.4274/tjps.galenos.2021.95680, PMID 34719186.

4. US Food and Drug Administration. Oral dosage strength physicochemical and pharmacokinetic data; 2008. Available from: https://www.accessdata.fda.Gov/drugsatfda_docs/label/2008/021743s010lbl.pdf.

5. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib an inhibitor of the epidermal growth factor receptor tyrosine kinase in a randomized crossover study in healthy subjects. J Clin Pharmacol. 2006;46(3):282-90. doi: 10.1177/0091270005284193, PMID 16490804.

6. Gala UH, Miller DA, Williams RO. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188319. doi: 10.1016/j.bbcan.2019.188319, PMID 31678141.

7. Fan L, Hu L, Yang B, Fang X, Gao Z, Li W. Erlotinib promotes endoplasmic reticulum stress mediated injury in the intestinal epithelium. Toxicol Appl Pharmacol. 2014;278(1):45-52. doi: 10.1016/j.taap.2014.04.015, PMID 24768708.

8. Geetha VS, Velraj M. Design development and in vitro evaluation of erlotinib loaded liquorice crude protein nanoparticles by box-behnken design. Int J App Pharm. 2021;13(4):94-101. doi: 10.22159/ijap.2021v13i4.41580.

9. Vrignaud S, Hureaux J, Wack S, Benoit JP, Saulnier P. Design optimization and in vitro evaluation of reverse micelle loaded lipid nanocarriers containing erlotinib hydrochloride. Int J Pharm. 2012;436(1-2):194-200. doi: 10.1016/j.ijpharm.2012.06.026, PMID 22721853.

10. Zhou Z, Kennell C, Jafari M, Lee JY, Ruiz Torres SJ, Waltz SE. Sequential delivery of erlotinib and doxorubicin for enhanced triple negative breast cancer treatment using polymeric nanoparticle. Int J Pharm. 2017;530(1-2):300-7. doi: 10.1016/j.ijpharm.2017.07.085, PMID 28778627.

11. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018;10(4):191. doi: 10.3390/pharmaceutics10040191, PMID 30340327.

12. Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Adv Pharm Bull. 2022;12(1):17-33. doi: 10.34172/apb.2022.007, PMID 35517874.

13. Akanda M, Mithu MS, Douroumis D. Solid lipid nanoparticles: an effective lipid based technology for cancer treatment. J Drug Deliv Sci Technol. 2023 Sep;86:104709. doi: 10.1016/j.jddst.2023.104709.

14. Dudhipala N, Janga KY. Lipid nanoparticles of zaleplon for improved oral delivery by box-behnken design: optimization in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(7):1205-14. doi: 10.1080/03639045.2017.1304957, PMID 28274147.

15. Amit Kumar S, Alok M, Himanshu P, Shanti Bhushan M. Fabrication of solid lipid nanoparticles by hot high shear homogenization and optimization by box-behnken design: an accelerated stability assessment. J Appl Pharm Sci. 2021;11(9):35-47. doi: 10.7324/JAPS.2021.110905.

16. Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int J Pharm. 2017;534(1-2):1-13. doi: 10.1016/j.ijpharm.2017.09.071, PMID 28970115.

17. Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility dissolution rate in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2016 Feb 10;137:339-49. doi: 10.1016/j.carbpol.2015.10.080, PMID 26686138.

18. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-77. doi: 10.1016/s0939-6411(00)00087-4, PMID 10840199.

19. Mehnert W, Mader K. Solid lipid nanoparticles: production characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-96. doi: 10.1016/s0169-409x(01)00105-3, PMID 11311991.

20. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-84. doi: 10.1016/j.ijpharm.2008.10.003, PMID 18992314.

21. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Physiol Sci. 2014;25(1):59-75.

22. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300. PMID 18019829.